chartexchange

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire Inc. | Nov 12, 2026 8:00 AM EST

IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer

Read original article